MiraeING.Co.,Ltd. Stock

Equities

A007120

KR7007120009

Financial Technology (Fintech)

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
1,144 KRW +0.26% Intraday chart for MiraeING.Co.,Ltd. -4.59% -18.58%
Sales 2021 7.81B 5.67M Sales 2022 12.83B 9.31M Capitalization 36.86B 26.76M
Net income 2021 -18.08B -13.13M Net income 2022 -3.03B -2.2M EV / Sales 2021 6.36 x
Net cash position 2021 10.84B 7.87M Net cash position 2022 849M 616K EV / Sales 2022 2.81 x
P/E ratio 2021
-3.34 x
P/E ratio 2022
-12.1 x
Employees 38
Yield 2021 *
-
Yield 2022
-
Free-Float 74.91%
More Fundamentals * Assessed data
Dynamic Chart
MiraeING.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on MiraeING.Co.,Ltd.'s Equity Buyback Plan announced on September 29, 2022. CI
Tranche Update on MiraeING.Co.,Ltd.'s Equity Buyback Plan announced on September 29, 2022. CI
MiraeING.Co.,Ltd.'s Equity Buyback announced on September 29, 2022, has expired with 6,960,223 shares, representing 5.02% for KRW 2,183.64 million. CI
MiraeING.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
MiraeING.Co.,Ltd. announces an Equity Buyback for 13,100,500 shares. CI
MiraeING.Co.,Ltd. authorizes a Buyback Plan. CI
MiraeING.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
MiraeING.Co.,Ltd. announced that it has received KRW 3.000000352 billion in funding from X. Co., Ltd, Namsan Mulsan Co., Ltd. CI
MiraeING.Co.,Ltd. announced that it expects to receive KRW 3.000000352 billion in funding from X. Co., Ltd, Namsan Mulsan Co., Ltd. CI
Fantagio Corp. announced that it has received KRW 7.00000046 billion in funding from MiraeING.Co.,Ltd. CI
Fantagio Corp. announced that it expects to receive KRW 7.999999132 billion in funding from MiraeING.Co.,Ltd. CI
MiraeING.Co.,Ltd. agreed to acquire an additional 49.7% stake in ArtistCosmetics. Co., Ltd. for KRW 4.2 billion. CI
Fantagio Corp. announced that it has received KRW 9 billion in funding from MiraeING.Co.,Ltd. CI
MiraeING.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
More news
1 day+0.26%
1 week-4.59%
Current month-8.04%
1 month-10.49%
3 months-5.22%
6 months+3.81%
Current year-18.58%
More quotes
1 week
1 085.00
Extreme 1085
1 201.00
1 month
1 076.00
Extreme 1076
1 274.00
Current year
1 055.00
Extreme 1055
1 430.00
1 year
1 040.00
Extreme 1040
2 440.00
3 years
1 040.00
Extreme 1040
3 850.00
5 years
1 040.00
Extreme 1040
3 850.00
10 years
1 040.00
Extreme 1040
12 300.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 -
Director/Board Member 67 -
Corporate Officer/Principal 64 -
Members of the board TitleAgeSince
Chief Executive Officer 46 -
Director/Board Member 67 -
Director/Board Member 34 -
More insiders
Date Price Change Volume
24-04-25 1,144 +0.26% 88 511
24-04-25 1,141 -1.47% 70,244
24-04-24 1,158 +3.95% 275,408
24-04-23 1,114 -0.62% 94,525
24-04-22 1,121 -2.10% 127,028

End-of-day quote Korea S.E., April 25, 2024

More quotes
MiraeING.Co.,Ltd., formerly Theall Medi Bio. Co.,Ltd., is a Korea-based company mainly engaged in solution business and video business. The Company operates in three main segments: solution segment, which provides project consulting, construction and maintenance services and related products for banks under the brand name XiT, eNisis and others; video segment, which provides digital video recorders (DVRs) and closed circuit television (CCTV) systems for security areas, and defense segment, which provides self-propelled artilleries and components. It also engages in the leasing of non-residential buildings.
More about the company
  1. Stock Market
  2. Equities
  3. A007120 Stock